Carey Danis & Lowe Pelvic Mesh Lawyers Weigh in on Ethicon MDL 2327 and Gynecare Prolift Mesh Lawsuit Removal Request
Published April 25, 2013 by PR Web St. Louis, Missouri (PRWEB) April 25, 2013 Pelvic mesh lawyers at Carey Danis & Lowe continue to follow Ethicon MDL 2327 proceedings currently taking place in the U.S. District Court for the Southern District of West Virginia, as the law firm represents women who have been injured by defective pelvic mesh. A recent update in the Ethicon MDL involves a pretrial order issued by Chief Judge Robert C. Chambers and U.S. District Judge Joseph R. Goodwin. The order pertains to the judge responsible for Continue Reading
Flores v. Ethicon: Transvaginal Mesh Trial Memorandum Opinion & Order
IN THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF WEST VIRGINIA CHARLESTON DIVISION DAWN FLORES, et al., Plaintiffs, v. CIVIL ACTION NO. 2:12-cv-01804 ETHICON, INC., et al., Defendants. MEMORANDUM OPINION AND ORDER Pending before the court is the plaintiffs’ Motion to Remand [Docket 13]. The plaintiffs also seek sanctions. For the reasons discussed below, the motion to remand and the request for sanctions are DENIED. I. Background This case is one of several thousand assigned to me by the Judicial Panel on Multidistrict Litigation (hereinafter the “MDL Continue Reading
Discussions Underway in Forming Mirena MDL: Bayer Opposes Consolidating into Mirena MDL
Submit Your Claim A U.S. Judicial Panel on Multi-district Litigation (JPML) met on March 21 in San Diego, California to discuss the consolidation of Mirena IUD lawsuits into a multi-district litigation (MDL). Bayer, the manufacturer of the Mirena intrauterine device (IUD), has expressed a strong opposition against consolidation of lawsuits into an MDL. The German pharmaceutical company opposes the formation of a Mirena MDL, which the Judicial Panel is calling In re: Mirena IUD Products Liablity Litigation, MDL No. 2434, because Bayer believes that a Mirena MDL would stall Continue Reading
Lawyers at Carey Danis & Lowe Currently Evaluating Mirena Cases
Submit Your Claim Published February 20, 2013 by PR Web St. Louis, Missouri (PRWEB) February 20, 2013 To address the increasing number of adverse event reports associated with the use of the Mirena intrauterine device manufactured by Bayer(1), lawyers at Carey Danis & Lowe have launched a new website with useful information for individuals who may have used the Mirena IUD or know someone who has used the contraceptive device. The new webpage has information about health complications associated with use of Bayer’s Mirena IUD. In Carey Danis & Continue Reading
Levaquin MDL Settlement Update: Phase 1 Plaintiffs Have Signed a Settlement Agreement
Submit Your Claim Court convened on January 8, 2013 for a Status Conference for Levaquin lawsuits that have been consolidated into In Re: Levaquin Products Liability Litigation, the Multi-District Litigation (MDL) that is being heard by U.S. District Judge John R. Tunheim in the U.S. District Court for the District of Minnesota. Though the plaintiffs’ committee and the defendant’s representation only met for a half hour, they brought forth important updates in the Levaquin MDL. According to information provided by the Defendants, there are currently 1000 cases pending in Continue Reading
Minnesota Levaquin MDL and New Jersey Levaquin Mass Tort Plaintiffs Claim Serious Tendon Damage
Submit Your Claim Levaquin, a drug manufactured by a Johnson & Johnson subsidiary – OrthoMcNeil Pharmaceutical, Inc. – is the topic of several lawsuits around the country that have since been consolidated into a Multi-District Litigation based in Minnesota. A mass tort litigation has been arranged in a New Jersey court. Levaquin is a drug used to treat bacterial infections occurring in the lungs, urinary tract, skin, and other areas of the body. It soon became apparent that Levaquin was the cause of serious and painful side effects, primarily Continue Reading
European Medicines Agency’s Takes a Stand on Actos
Submit Your Claim The European Medicines Agency made an effort to provide more detail on its conclusion regarding the safety of drugs containing pioglitazone, including the diabetes drug Actos. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded in July 2011 that in patients taking medicines containing pioglitazone, such as Actos, their researchers observed an increased risk in the development of bladder cancer. Though the European Medicines Agency recognizes the risk for patients to develop bladder cancer, they are still recommending that doctors prescribe drugs Continue Reading
Contraceptive Nuvaring Linked to Blood Clots and Stroke
Published November 12, 2012 by LawsuitInformation.org Nuvaring is a contraceptive device manufactured by Organon. It was approved by the U.S. Food and Drug Administration (FDA) in 2001. Organon developed and manufactured Nuvaring on the premise of introducing a new form of birth control, one that would supposedly be easier for women to use. However, it soon became apparent after the release of Nuvaring that there were serious issues with the contraceptive device. Questions began to arise as to the verity of Organon’s marketing campaign promoting Nuvaring, especially regarding third-generation Continue Reading
Antidepressant Wellbutrin Linked to Birth Defects
Published October 23, 2012 by LawsuitInformation.org Manufactured by pharmaceutical giant GlaxoSmithKline, Wellbutrin is an antidepressant drug that has been linked to congenital birth defects. The U.S. Food and Drug Administration (FDA) approved the antidepressant medication Wellbutrin (bupropion) in order to treat depression. Due to the increasing occurrences of life-threatening and life-altering birth defects connected with the use of Wellbutrin in pregnant mothers, the FDA has categorized Wellbutrin as a pregnancy category C drug. Unlike many antidepressants on the market that block serotonin, Wellbutrin is categorized as a norepinephrine and Continue Reading
Federal Trade Commission Concludes Investigation into Bayer Pharmaceuticals and Yasmin Patent Litigation
Published October 12, 2012 by LawsuitInformation.org In recent news regarding Bayer Pharmaceuticals, the German pharmaceutical giant responsible for the manufacture of Yaz and Yasmin, the Federal Trade Commission made the decision to terminate its investigation into a patent settlement between Bayer and Teva Pharmaceuticals. In 2008, the two pharmaceutical companies reached an agreement in regards to Bayer’s claim that Barr Laboratories, which was ultimately purchased by Teva Pharmaceuticals, overstepped the boundaries of intellectual property protecting Bayer’s Yasmin patent. The 2008 settlement drew the attention of the FTC, and led Continue Reading
